A carregar...
CIK Cells and HDAC Inhibitors in Multiple Myeloma
Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4–5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitor...
Na minha lista:
| Publicado no: | Int J Mol Sci |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5454858/ https://ncbi.nlm.nih.gov/pubmed/28468247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18050945 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|